Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | STK11 F298L |
Therapy | Everolimus + Radiotherapy |
Indication/Tumor Type | pituitary carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
STK11 F298L | pituitary carcinoma | predicted - sensitive | Everolimus + Radiotherapy | Case Reports/Case Series | Actionable | In a clinical case study, a patient with adenocorticotropic pituitary carcinoma harboring STK11 F298L demonstrated stable disease and clinical benefit for greater than 6 months following treatment with Afinitor (everolimus), along with radiotherapy (PMID: 27615706). | 27615706 |
PubMed Id | Reference Title | Details |
---|---|---|
(27615706) | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. | Full reference... |